Home/Pipeline/SBX 1988

SBX 1988

Diabetes

Early-stage ClinicalActive

Key Facts

Indication

Diabetes

Phase

Early-stage Clinical

Status

Active

Company

Stramsen Biotech

About Stramsen Biotech

Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Diseases Infectious Disease (HIV)Metabolic Disorders (Diabetes)Neurological Disorders Musculoskeletal Disorders (Arthritis)Urology Wound Care Nephrology

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active